Interim CEO; Executive Vice President and Chief Financial Officer
Matt David was appointed Executive Vice President and Chief Financial Officer in May 2020. He leads the Company’s finance and investor relations activities. Prior to joining CorMedix, Dr. David was Head of Strategy at Ovid Therapeutics and spent the majority of his career in healthcare investment banking roles where he advised life sciences companies on a broad range of financing and strategic transactions. Earlier in his career, Dr. David spent time as a research analyst covering the pharma sector. Dr. David received his M.D. from NYU School of Medicine and his undergraduate degree from Dartmouth College.
Executive Vice President and General Counsel
Phoebe Mounts was appointed Executive Vice President and General Counsel in May 2019. She leads the Company’s legal, compliance and regulatory affairs activities. Prior to joining CorMedix, Dr. Mounts was a partner at the law firm Morgan Lewis and Bockius LLP where since 2013 she advised the Company with respect to its FDA regulatory strategies for Defencath™ and taurolidine. Dr. Mounts is a graduate of Georgetown University Law Center, prior to which she was on the faculty of the Johns Hopkins University School of Public Health for 16 years, specializing in molecular biology and infectious disease. She received her Ph.D. in molecular biology from the University of Edinburgh in Scotland.
Executive Vice President and Chief Commercial Officer
Tom Nusbickel joined CorMedix in May 2021. He has more than 30 years of experience in the pharmaceutical industry with a focus on commercial launches, brand building and market access. Most recently, he served as Vice President of Market Access and Government Affairs at Coherus Biosciences, a leader in biosimilars. Previously, Tom served as Chief Commercial Officer at Opko Inc, leading an 80-person renal disease business unit and overseeing the commercial planning and launch for Rayaldee®. Before joining Opko, Tom spent more than two decades with Amgen, gaining leadership experience across domestic and international marketing roles, including a decade involved with the successful global launch of Sensipar®, a product for End Stage Renal Disease patients on hemodialysis. Tom received his undergraduate degree from Eckerd College and earned an MBA degree from Pepperdine University.
Executive Vice President and Head of Clinical Operations
Liz Masson-Hurlburt serves as our Executive Vice President and Head of Clinical Operations. Prior to that, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as Vice President, Clinical Operations. Responsible for strategic and operational development activities, Liz has a passion for growing and developing highly engaged teams and assuring the highest standards for program execution. Liz received her B.A. in Leadership and Organizational Management from Bay Path College.
Adviser Chief Medical Officer
Paul Chew, M.D., has been a Consultant Adviser Chief Medical Officer at CorMedix, Inc. since May 2018. He previously served as Group Chief Medical Officer, Senior Vice President and Head of Sanofi R&D North America Hub of Sanofi-Aventis U.S. LLC. from 2007 to 2016. Prior to Sanofi U.S. , Dr. Chew served as Vice President, Global Head of Metabolism & Diabetes at Aventis Pharmaceuticals from 2001 to 2004. He is a member of the PhRMA Science & Regulatory Affairs Executive Committee and the Institute of Medicine Value & Science-Driven Healthcare Roundtable. He has a substantial history of working with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) including lead sponsor representation at FDA Advisory Committees and EMA Scientific Advisory Groups. Dr. Chew received his medical degree from The Johns Hopkins School of Medicine. Dr. Chew has spent more than 20 years at the Johns Hopkins University and School of Medicine, where he received his B.Sc. in Human Biology, completed his residency, and held various faculty positions.